spacer
home > ebr > Spring 2017
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2017

   
Text
PDF
Editor’s Letter

Dr Deborah O’Neil, Editor of EBR, highlights the connections and debates that interlink the articles by our contributors this issue, with a particular focus on the protein problem and the need for tighter regulation across fields such as biomarkers and personalised medicine.
 
view
download pdf
bullet
Drug Discovery
Biological Complexity & Drug Discovery

A Complex System


When considering the cell as a complex system it is possible to uncover new opportunities in drug discovery, says Jonny Wray at e-Therapeutics – and their applications are wide-ranging and certainly beneficial.
 
view
download pdf
Identifying the Need for New Drugs

Opening Doors


Benoît Laleu, Jaya Banerji and Paul A Willis at Medicines for Malaria Venture discuss the Malaria and Pathogen Boxes, which emphasise the importance and benefits of collaboration and open source approaches in drug discovery.
 
view
download pdf
bullet
BUSINESS STRATEGY
In Brief

Just Value


Emile Bellott, EBR’s Industry Advisor, investigates how to successfully create a supply-side business model taking into account value in negotiating with manufacturers on drug prices.
 
view
download pdf
CDMO Developments

Seize the Market


Rentschler Biotechnologie’s Dr Stefan R Schmidt and Dr Birgit Schwab investigate how mid-size contract development and manufacturing organisations can take advantage of the biopharmaceutical market. Updating their facilities and researching personalised medicines, they argue, could be the answer.
 
view
download pdf
bullet
RESEARCH AND DEVELOPMENT
Spotlight

Managing E&L Unknown Compounds


With unknown compound characterisation representing a challenging aspect of analytical chemistry, Eurofins BioPharma Product Testing investigates extractables and leachables as well as the importance of knowing your compounds.
 
view
download pdf
bullet
CELL-BASED RESEARCH
Cells and Serums

Culture Clash


Jessie HT Ni at Irvine Scientific explores the latest developments in the world of serums. With their benefits and risks well known, we are beginning to further understand their effects on phenotypes and, as a result, our knowledge of cell biology is expanding.
 
view
download pdf
Q&A: Genetic Modification

Express Yourself


We learn about the possibilities of cell engineering, genetic modification and protein production in this Q&A feature with the team at Oxford Genetics, who say that it could be possible to cure inherited diseases with new technology.
 
view
download pdf
bullet
THERAPEUTIC DEVELOPMENT
Protein Identification

Becoming Better Informed


Christian Loch at AVMBioMed suggests that proteomics may be the best tool for characterising investigational molecules and identifying useful biomarkers. However, this needs to be done more reproducibly and should account for post-translational modification.
 
view
download pdf
Biomarkers and Personalised Medicine

Essential Tools


Dr Mélanie Bodnar-Wachtel and Dr Tanja Schubert at Bioclinica Lab reveal how biomarkers are being used in the treatment of Alzheimer’s disease and cancer. As they become essential, they are revolutionising the manufacture of advanced therapies and allowing for new and innovative practices and partnership.
 
view
download pdf
Therapeutic Transportation

Stay Cool


When transporting manufactured drugs, there are many factors that have the potential to damage product integrity. John Fink and Katheryn Shea at Brooks Life Science Systems explore best practices to avoid this with regards to cryopreservation.
 
view
download pdf
Protein Production

Balancing Act


Cytovance’s April Stanley explores different approaches for successful therapeutic protein production. The most effective ones, she argues, involve both integration and partnership.
 
view
download pdf
Patient Stratification

Personalised Immuno-Oncology


As global cancer diagnoses are set to surge, the implementation of biomarkers like autoantibodies could be a saving grace for the development of effective immunotherapies in the field of oncology, argue Dr Peter Schulz-Knappe and Dr Georg Lautscham at Protagen.
 
view
download pdf
Q&A: Biomarkers in Oncology

Pinpointing the Problem


ICON LaboratoriesDr Mario L Rocci Jr shares his insights on the use of biomarkers in oncology with particular focus on PD-L1 and tumour-infiltrating lymphocytes.
 
view
download pdf
Influenza Viruses

Going Viral


Human challenge trials could lead the way in real world validation of medication efficacy, believes Adrian Wildfire at SGS Life Sciences. He states that various strains of the influenza virus are acceptable candidates for such studies, and explains some of the reasons why they are so effective.
 
view
download pdf
Peptides and Proteomics

Perfecting Progress


Although proteomics lacks sufficient global legislative procedures, Kim Plasman, Kris Gevaert, Francis Impens and Tony Montoye put forward several methods for improving the quality of workflows through accurate peptide quantification.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics

IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement